top of page

The COVAIL Trial
Phase 2 Study
(No Longer Recruiting)

The COVID-19 VAriant Immunologic Landscape Trial, also known as COVAIL, is a vaccine trial designed to evaluate the immune response and safety of updated vaccines targeted to new circulating SARS-CoV-2 variants like Delta and Omicron.


The trial will compare the updated variant vaccines to a strategy of providing further boosters of the original EUA/FDA-approved vaccines. The trial will also evaluate whether combining vaccines against different strains is safe and can generate immunity against multiple variants simultaneously.

The ultimate goal? To find the best way to protect people from emerging variants as and when they appear.

Family 1
College Friends

PreventCovidU Study
(No Longer Recruiting)

Does the Moderna COVID-19 vaccine prevent spreading the virus to others? 


We want to know if the Moderna COVID-19 vaccine is able to protect people from getting infected with SARS-CoV-2 (which causes COVID-19 disease) and if getting the vaccine will affect the amount of virus that is in the nose. We also want to know if getting the vaccine will prevent transmitting SARS-CoV-2 to others.

We already know that this vaccine can prevent serious COVID-19 disease, but we do not know if the vaccine will prevent the virus from shedding from the nose and mouth and infecting others. That is what we are testing in this study.

(No Longer Recruiting)

AZD1222 is an investigational vaccine being developed by AstraZeneca to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.

The vaccine is based on a weakened version of a common cold (adenovirus) virus. The adenovirus vaccine has been changed so that it can’t replicate inside your body. It presents part of the COVID-19 spike protein to the body so that an immune response can be made to it. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and how safe it is.

Janssen Ensemble
(No Longer Recruiting)

​The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.

bottom of page